NDATOPICALCREAM
Approved
Dec 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
4/8 — Partial
LOPROX (ciclopirox) by Eurofarma Laboratórios is protein synthesis inhibitors [moa]. Approved for onychomycosis, foot dermatoses, dermatomycoses. First approved in 1982.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOPROX (ciclopirox) is a topical cream antifungal agent that inhibits fungal protein synthesis by chelating polyvalent cations, used to treat onychomycosis, foot dermatoses, and other dermatomycoses. It is a small-molecule topical formulation approved in 1982 with limited systemic absorption (<5% of applied dose). The drug addresses fungal nail infections and related dermatological conditions in patients seeking non-systemic treatment options.
LOE Approaching
Product is in late-stage lifecycle with declining market relevance; team size and hiring likely minimal as focus shifts to generic transition or pipeline advancement.
Mechanism of Action
Protein Synthesis Inhibitors
Indications (3)
Worked on LOPROX at Eurofarma Laboratórios? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.